Bots, editor, reviewer, Administrators
13,941
edits
No edit summary Tag: Reverted |
No edit summary Tag: Manual revert |
||
Line 7,488: | Line 7,488: | ||
"title" : "Closure of patent foramen ovale versus medical therapy after cryptogenic stroke", | "title" : "Closure of patent foramen ovale versus medical therapy after cryptogenic stroke", | ||
"pmid" : "23514286" | "pmid" : "23514286" | ||
}, | |||
{ | |||
"timestamp" : "2017-12-03T22:39:03Z", | |||
"briefDesignDescription" : "Rifaximin/lactulose vs. lactulose for acute HE", | |||
"fulltexturl" : "http://www.nature.com/ajg/journal/v108/n9/full/ajg2013219a.html", | |||
"pageid" : 1784, | |||
"pdfurl" : "http://www.nature.com/ajg/journal/v108/n9/pdf/ajg2013219a.pdf", | |||
"trainingLevel" : "Intern", | |||
"citation" : "Sharma BC, <i>et al</i>. \"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy\". <i>The American Journal of Gastroenterology</i>. 2013. 108(9):1458-1463.", | |||
"subspecialties" : "Gastroenterology", | |||
"expansion" : "", | |||
"statusUsableDate" : "2014-03-01", | |||
"briefResultsDescription" : "Rifaximin/lactulose improved rates of HE reversal and survival, reduced hospital LOS", | |||
"published" : "2013-09-01", | |||
"pageName" : "Rifaximin and Lactulose for HE", | |||
"diseases" : "Hepatic Encephalopathy", | |||
"abbreviation" : "", | |||
"title" : "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", | |||
"pmid" : "23877348" | |||
}, | |||
{ | |||
"timestamp" : "2022-03-10T21:09:46Z", | |||
"briefDesignDescription" : "Rituximab in ANCA-Renal Vasculitis", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/nejmoa0909169", | |||
"pageid" : 4459, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa0909169", | |||
"trainingLevel" : "fellow", | |||
"citation" : "Jones RB, <i>et al</i>. \"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis\". <i>The New England Journal of Medicine</i>. 2010. 363(3):211-232.", | |||
"subspecialties" : "Rheumatology;Nephrology", | |||
"expansion" : "", | |||
"statusUsableDate" : "2022-03-10", | |||
"briefResultsDescription" : "Rituximab not superior to cyclophosphamide", | |||
"published" : "2010-07-15", | |||
"pageName" : "RITUXVAS", | |||
"diseases" : "Vasculitis;ANCA-Associated Vasculitis;Renal Vasculitis", | |||
"abbreviation" : "RITUXVAS", | |||
"title" : "Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis", | |||
"pmid" : "20647198" | |||
}, | }, | ||
{ | { |